Hospital Israelita Albert Einstein.
University of Florida College of Dentistry, Gainesville, FL.
J Immunother. 2019 Nov/Dec;42(9):359-362. doi: 10.1097/CJI.0000000000000280.
Pembrolizumab is a humanized antibody that targets the programmed death-1 receptor expressed in T cells with high selectivity. This therapeutic is of great importance in cancer immunotherapy yet managing the potential immune-related adverse events remains a concern. Here, we report a rare case of mucous membrane pemphigoid in the oral mucosa, upper respiratory tract, and conjunctiva of a patient with ovarian adenocarcinoma without cutaneous manifestation, which persisted even after pembrolizumab discontinuation. A brief review of pembrolizumab-related bullous pemphigoid cases is presented and possible mechanisms underlying these lesions are discussed.
帕博利珠单抗是一种人源化抗体，靶向 T 细胞中高选择性表达的程序性死亡受体-1。这种治疗药物在癌症免疫治疗中具有重要意义，但管理潜在的免疫相关不良反应仍然是一个关注点。在这里，我们报告了一例卵巢腺癌患者口腔黏膜、上呼吸道和结膜罕见的黏膜类天疱疮病例，即使在停用帕博利珠单抗后仍持续存在。本文简要回顾了与帕博利珠单抗相关的大疱性类天疱疮病例，并讨论了这些病变的可能机制。
